机译:诊所的人类基因组编辑:监管效益风险评估中的新挑战
Berlin-Brandenburg Center for Regenerative Therapies (BCRT) Charité–Universit?tsmedizin Berlin;
Institute for Transfusion Medicine and Gene Therapy Medical Center– University of Freiburg;
Division of Medical Biotechnology Paul-Ehrlich-Institut Langen Germany;
Center for Cellular Therapies University of Pennsylvania Perelman School of Medicine Philadelphia;
Division of Medical Biotechnology Paul-Ehrlich-Institut Langen Germany;
National Institute for Biological Standards and Control (NIBSC) Medicines and Healthcare Products;
University of California Davis Institute for Regenerative Cures (IRC) Sacramento CA USA;
genome editing; regulations; clinical trials; safety; efficacy; benefit-risk assessment; off-target effects;
机译:诊所的人类基因组编辑:监管效益风险评估中的新挑战
机译:人类基因组编辑种族:松动的商业优势监管标准吗?
机译:人类调节性T细胞在临床中的前景与挑战
机译:监管框架中人类可靠性评估的责任与挑战
机译:监管决策中药物利益风险评估的新型定量方法:案例研究和政策分析。
机译:全基因组关联研究和CRISPR / Cas9介导的基因编辑确定了影响人类眉毛粗细的调节性变体
机译:改变人类基因组:绘制南非的基因组编辑监管系统